Figure 5 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma

作者：George Ansstas, Karam Khaddour, Sumedha Sudhaman, Karen Lin, Griffin Budde, Andrew Poklepovic, Bently P. Doonan, Meghan J. Mooradian, Ryan J. Sullivan, T. Vincent, Jeremy Rosiecki, Steven Liu, Ronald Drengler, Daniel Flora, Georgia M. Beasley, Kristen E. Rhodin, John Hyngstrom, Elise K. Brunsgaard, J. Bryce Ortiz, Giby V. George, Michael Krainock, Minetta C. Liu, Alan Tan · 年份：2026 · DOI：10.1158/1078-0432.32712855 · 研究领域：Cancer Genomics and Diagnostics、Cutaneous Melanoma Detection and Management、Single-cell and spatial transcriptomics

<p>Flow diagram depiction of ctDNA-driven changes in clinical management with representative case examples. Of the 190 patients included in our study, 34 had ctDNA positivity at any time point. Of these, clinical care was influenced by ctDNA positivity in 26 cases, ranging from imaging escalation to treatment initiation, switch, or escalation. MTM, mean tumor molecules; ND, not detected; NED, no evidence of disease; PR, partial response.</p>